title: Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
authors.affiliation: Departments of Oncology & Surgery, The Sidney Kimmel Cancer Center, & the Skip Viragh Center for Pancreatic Cancer Research & Clinical Care, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 488, Baltimore, MD 21231, USA.
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000628:therapy
chemical_list: D019496:Cancer Vaccines
keywords: PD-1; PD-L1; immunotherapy; pancreatic cancer; tertiary lymphoid aggregates; vaccine